

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)	<i>Complete if Known</i>	
	<b>Application Number</b>	10/597,803
	<b>Filing Date</b>	April 13, 2007
	<b>First Named Inventor</b>	Robert Tridgett
	<b>Group Art Unit</b>	1614
	<b>Examiner Name</b>	Craig Ricci
Sheet 1 of 5		Attorney Docket No: 3063.002US1

US PATENT DOCUMENTS				
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US-2,830,993	04/15/1958	Brossi, Arnold, et al.	05/18/1956
	US-2,843,591	07/15/1958	Brossi, Arnold, et al.	02/04/1957
	US-2,954,382	09/27/1960	Osbond, John Marvyn	07/28/1958
	US-3,009,918	11/21/1961	Openshaw, Harry Tacon, et al.	01/19/1959
	US-3,045,021	07/17/1962	Brossi, Arnold Riehen	09/13/1960
	US-3,053,845	09/11/1962	Tretter, James R	08/29/1961
	US-3,079,395	02/26/1963	Brossi, Arnold, et al.	03/26/1958
	US-3,095,419	06/25/1963	Tretter, James R	09/06/1961
	US-3,105,079	09/24/1963	Tretter, James R	12/29/1961
	US-3,123,609	03/03/1964	Openshaw, Harry Tacon, et al.	11/22/1960
	US-3,132,147	05/05/1964	Schopf, Clemens, et al.	06/15/1962
	US-3,159,638	12/01/1964	Ritchie, Alexander Crawford, et al.	08/20/1962
	US-3,209,005	09/28/1964	Brossi, Arnold, et al.	06/06/1963
	US-3,314,966	04/18/1967	Brossi, Arnold, et al.	04/06/1964
	US-3,342,825	09/19/1967	Openshaw, Harry Tacon, et al.	11/22/1960
	US-3,375,254	03/26/1968	Openshaw, Harry Tacon, et al.	09/17/1965
	US-3,390,152	06/25/1968	Harnden, Michael Raymond	10/21/1965
	US-3,634,431	01/11/1972	Van Dyke, John William	07/03/1967
	US-3,635,986	01/18/1972	Van Dyke, John William	12/22/1969
	US-4,076,820	02/28/1978	Archibald, John Leheup, et al.	05/13/1976
	US-4,102,886	07/25/1978	Szantay, Csaba, et al.	10/21/1975
	US-4,133,812	01/09/1979	Szantay, Csaba, et al.	04/25/1977
	US-4,304,913	12/08/1981	Havera, Herbert J, et al.	10/02/1980
	US-6,087,376	07/11/2000	Crooks, Peter A, et al.	06/03/1998

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T <sup>1</sup>
	WO-2005077946A1	08/25/2005	Clarke, Ian, et al.	

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	"European Application Serial No. 05708289.3, Response filed 09-17-07", 8 pgs	
	"International Application Serial No. PCT/GB2005/000464, International Search Report mailed 06-10-05", 4 pgs	
	"International Application Serial No. PCT/GB2005/000464, Preliminary Report on Patentability mailed 08-14-06", 9 pgs	

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)	<i>Complete if Known</i>	
	<b>Application Number</b>	10/597,803
	<b>Filing Date</b>	April 13, 2007
	<b>First Named Inventor</b>	Robert Tridgett
	<b>Group Art Unit</b>	1614
	<b>Examiner Name</b>	Craig Ricci
Sheet 2 of 5		Attorney Docket No: 3063.002US1

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	"International Application Serial No. PCT/GB2005/000464, Written Opinion mailed 06-10-05", 8 pgs	
	ALBIN, et al., "Increased Ventral Striatal Monoaminergic Innervation in Tourette Syndrome", <u>Neurology</u> 61, (2003), 310-315	
	BOHNEN, et al., "Decreased Striatal Monoaminergic Terminals in Huntington Disease", <u>Neurology</u> 54, (2000), 1753-1759	
	BORGHT, THIERRY VANDER, et al., "In Vivo Imaging of the Brain Vesicular Monoamine Transporter", <u>The Journal of Nuclear Medicine</u> , vol 36, No 12, (1995), 2252-2260	
	BORGHT, VANDER, et al., "[3H]Methoxytetraabenazine: A High Specific Activity Ligand for Estimating Monoaminergic Neuronal Integrity", <u>Neuroscience</u> Vol. 68, No. 3, (1995), 955-962	
	BROSSI, et al., "Synthese und absolute Konfiguration von (-)-2-Dehydroemetin", <u>Experientia</u> , (1962), 211-212	
	BROSSI, et al., "Syntheseversuche in der Emetin-Reihe 2. Mitteilung: Neue Reaktionen mit 3,4-dihydro-isochinolin", <u>Chimia</u> 12, (1958), 114-115	
	BROSSI, et al., "Syntheseversuche in der Emetin-Reihe 3. Mitteilung: 2-Hydroxy-hydrobenzo[a]chinolizine", <u>Helvetica Chimica Acta</u> volume XLI, Number 193, (1958), 1793-1806	
	BROSSI, et al., "Syntheseversuche in der Emetin-Reihe 4. Mitteilung: Racemisches 2-Dehydro-emetin", <u>Helvetica Chimica Acta</u> Vol 42, (1959), 772-788	
	BROSSI, et al., "Syntheseversuche in der Emetin-Reihe 7. Mitteilung: Abbau und Synthese substituierter 2-Oxo-hydrobenzo[a]chinolizine", <u>Helvetica Chimica Acta</u> , volume XLIII, No 77, (1960), 583-593	
	BROSSI, et al., "Syntheseversuche in der Emetinreihe 9. Mitteilung: Die Absolute Konfiguration von (-)-2-Dehydro-emetin", <u>Helvetica Chimica Acta</u> , volume XLV No 257, (1962), 2219-2226	
	BROSSI, et al., "Synthetic Experiments in the Emetine Series", <u>Helv. Chim. Acta</u> , vol. XLI, No. 193, (1958), 119-139	
	BRUDERER, et al., "Synthesen in der Emetin-Reihe 11. Mitteilung: 2-Arysubstituierte Hydrobenzo[a]chinolizine", <u>Helvetica Chimica Acta</u> , volume 47 No 203, (1964), 1852-1860	
	CANNEY, et al., "Amino- and Amido-Tetraabenazine Derivatives: Synthesis and Evaluation as Potential Ligands for the Vesicular Monoamine Transporter", <u>Nucl. Med. Biol.</u> 22, (1995), 527-535	
	DASILVA, et al., "Characterization of [11C]Tetraabenazine as an In Vivo Radioligand for the Vesicular Monoamine Transporter", <u>Nucl. Med. Biol</u> vol 21, No 2, (1994), 151-156	
	DASILVA, et al., "In Vivo Binding of [11C]Tetraabenazine to Vesicular Monoamine Transporters in Mouse Brain", <u>Life Sciences</u> Vol 51, (1992), 593-600	
	DASILVA, et al., "In Vivo Image of Monoaminergic Nerve Terminals in Mormal and MPTP-Lesioned Primate Brain Using Positron Emission Tomography (PET) and [11C]Tetraabenazine", <u>Synapse</u> 14, (1993), 128-131	

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)	<i>Complete if Known</i>	
	<b>Application Number</b>	10/597,803
	<b>Filing Date</b>	April 13, 2007
	<b>First Named Inventor</b>	Robert Tridgett
	<b>Group Art Unit</b>	1614
	<b>Examiner Name</b>	Craig Ricci
Sheet 3 of 5	Attorney Docket No: 3063.002US1	

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Include name of the author (In CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	DASILVA, et al., "Synthesis of a [11C]Methoxy Derivative of a-Dihydrotetrabenazine: A Radioligand for Studying Vesicular Monoamine Transporter", <u>Appl. Radiat. Isot. Vol 44 No. 12, (1993), 1487-1489</u>	
	DE SILVA, JEAN, et al., "Synthesis of [11C]Tetrabenazine, a Vesicular Monoamine Uptake Inhibitor, for PET Imaging Studies", <u>Appl. Radiat. Isot. vol 44: No 4, (1993), 673-676</u>	
	FLACK, et al., "Reporting and evaluating absolute-structure and absolute-configuration determinations", <u>Journal of Applied Crystallography 33, (2000), 1143-1148</u>	
	FREY, et al., "Imaging of Monoaminergic and Cholinergic Vesicular Transporters in the Brain", <u>Advances in Pharmacology Vol. 42, (1998), 269-272</u>	
	FREY, et al., "Presynaptic Monoaminergic Vesicles in Parkinsons Disease and Normal Aging", <u>Ann. Neurol. 40, (1996), 873-884</u>	
	GERECKE, M, et al., "Synthesversuche in der Emetin-Reihe 10. Mitteilung: Zur Oxydation von 2-Dehydro-emetin-Verbindungen mit Quecksilber(II)-acetat", <u>Helvetica Chimica Acta, volume 47 No. 121, (1964), 1117-1123</u>	
	GILMAN, et al., "Decreased Striatal Monoaminergic Terminals in Olivopontocerebellar Atrophy and Multiple System Atrophy Demonstrated with Positron Emission Tomography", <u>Ann. Neurol 40, (1996), 885-892</u>	
	JEWETT, et al., "A Simple Synthesis of [11C]Dihydrotetrabenazine (DTBZ)", <u>Nuclear Medicine and Biology, volume 24, (1997), 197-199</u>	
	KILBOURN, et al., "Differential Effects of Scopolamine on in Vivo Binding of Dopamine Transporter and Vesicular Monoamine Transporter Radioligands in Rat Brain", <u>Experimental Neurology 188, (2004), 387-390</u>	
	KILBOURN, et al., "Effects of Dopaminergic Drug Treatments on In Vivo Radioligand Binding to Brain Vesicular Monoamine Transporters", <u>Nuclear Medicine and Biology Vol 23, (1996), 467-471</u>	
	KILBOURN, et al., "In Vitro and In Vivo Studies of Benzisoquinoline Ligands for the Brain Synaptic Vesicle Monoamine Transporter", <u>J. Med. Chem. 39, (1996), 191-196</u>	
	KILBOURN, et al., "In Vivo Imaging of Vesicular Monoamine Transporters in Human Brain Using [11C]Tetrabenazine and Positron Emission Tomography", <u>Journal of Neurochemistry, vol 60, No 6, (1993), 2315-2318</u>	
	KILBOURN, et al., "In Vivo Measures of Dopaminergic Radioligands in the Rat Brain: Rquilibrium Infusion Studies", <u>Synapse 43, (2002), 188-194</u>	
	KILBOURN, "Long-term reproducibility of in vivo measures of specific binding of radioligands in rat brain", <u>Nuclear Medicine and Biology 31, (2004), 591-595</u>	
	KILBOURN, et al., "Mutant Mouse Strains as Models for In Vivo Radiotracer Evaluations: [11C]Methoxytetrabenazine ([11C]MTBZ) in Tottering Mice", <u>Nucl. Med. Biol. vol 22, No 5, (1995), 565-567</u>	
	KILBOURN, et al., "Pet Radioligands for Vesicular Neurotransmitter Transporters", <u>Med. Chem. Res. 5, (1994), 113-126</u>	

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center; padding: 2px;">Complete if Known</th> </tr> <tr> <td style="width: 50%; padding: 2px;"><b>Application Number</b></td> <td style="padding: 2px;">10/597,803</td> </tr> <tr> <td style="padding: 2px;"><b>Filing Date</b></td> <td style="padding: 2px;">April 13, 2007</td> </tr> <tr> <td style="padding: 2px;"><b>First Named Inventor</b></td> <td style="padding: 2px;">Robert Tridgett</td> </tr> <tr> <td style="padding: 2px;"><b>Group Art Unit</b></td> <td style="padding: 2px;">1614</td> </tr> <tr> <td style="padding: 2px;"><b>Examiner Name</b></td> <td style="padding: 2px;">Craig Ricci</td> </tr> </table>	Complete if Known		<b>Application Number</b>	10/597,803	<b>Filing Date</b>	April 13, 2007	<b>First Named Inventor</b>	Robert Tridgett	<b>Group Art Unit</b>	1614	<b>Examiner Name</b>	Craig Ricci
Complete if Known													
<b>Application Number</b>	10/597,803												
<b>Filing Date</b>	April 13, 2007												
<b>First Named Inventor</b>	Robert Tridgett												
<b>Group Art Unit</b>	1614												
<b>Examiner Name</b>	Craig Ricci												
Sheet 4 of 5	Attorney Docket No: 3063.002US1												

<b>OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS</b>		
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	KILBOURN, et al., "Rapid and Differential Losses of In Vivo Dopamine Transporter (DAT) and Vesicular Monoamine Transporter (VMAT2) Radioligand Binding in MPTP-Treated Mice", <u>Synapse</u> 35, (2000), 250-255	
	KILBOURN, et al., "The vesicular monoamine transporter is not regulated by dopaminergic drug treatments", <u>Eur. J. Pharmacol.</u> , (1995), 577-583	
	KILBOURN, "Time-Dependent Recovery of In Vivo Binding Sites after Drug Dosing: A Method of Radiotracer Evaluation", <u>Nuclear Medicine and Biology</u> Vol 24, (1997), 115-118	
	KOEPPE, et al., "Assessment of Extrastriatal Vesicular Monoamine Transporter Binding Site Density Using Stereoisomers of [11C]Dihydrotetrabenazine", <u>Journal of Cerebral Blood Flow and Metabolism</u> 19, (1999), 1376-1384	
	KOEPPE, et al., "Dual-[11C]Tracer Single-Acquisition Positron Emission Tomography Studies", <u>Journal of Cerebral Blood Flow and Metabolism</u> 21, (2001), 1480-1492	
	KOEPPE, et al., "Equilibrium Versus Compartmental Analysis for Assessment of the Vesicular Monoamine Transporter Using (+)-a-[11C]Dihydrotetrabenazine (DTBZ) and Positron Emission Tomography", <u>Journal of Cerebral Blood Flow and Metabolism</u> 17, (1997), 919-931	
	KOEPPE, et al., "Kinetic Evaluation of [11C]Dihydrotetrabenazine by Dynamic PET: Measurement of Vesicular Monoamine Transporter", <u>Journal of Cerebral Blood Flow and Metabolism</u> 16, (1995), 1288-1299	
	MEHVAR, et al., "Concentration-Effect Relationships of Tetrabenazine and Dihydrotetrabenazine in the Rat", <u>J. Pharm. Sci.</u> 76 no. 6, (1987), 461-465	
	MEHVAR, et al., "Pharmacokinetics of Tetrabenazine and its Major Metabolite in Man and Rat", <u>Drug Metab. Disp</u> 15, (1987), 250-255	
	ONDO, WILLIAM G, et al., "Tetrabenazine Treatment for Tardive Dyskinesia: Assessment by Randomized Videotape Protocol", <u>Am J Psychiatry</u> 156:8, (1999), 1279-1281	
	OSBOND, J M, "Chemical Constitution and Amoebicidal Activity. Part VI. a New Synthesis of 2-Keytones and 2-Alcohols derived from 3-Alkyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo[a]quinolizines", <u>J. Chem. Soc.</u> , (1961), 4711-4718	
	PLETSCHER, et al., "Benzoquinolizine Derivatives: A New Class of Monoamine Decreasing Drugs with Psychotropic Action", <u>Int. Rev. Neurobiol.</u> 4, (1962), 275-306	
	ROBERTS, et al., "The Pharmacokinetics of Tetrabenazine and its Hydroxy Metabolite in Patients Treated for Involuntary Movement Disorders", <u>European J. Clinical Pharmacology</u> 29, (1986), 703-708	
	RUBIRALTA, et al., "NMR Spectroscopy and X-Ray Crystallography of Benzo [a] Quinolizidines", <u>Heterocycles</u> 27, (1988), 1653-1664	
	SCHERMAN, et al., "Hydrophobicity of the Tetrabenazine-Binding Site of the Chromaffin Granule Monoamine Transporter", <u>Molecular Pharmacology</u> 33, (1988), 72-77	
	SCHWARTZ, et al., "Metabolic Studies of Tetrabenazine a Psychotropic Drug in Animals and Man", <u>Biochemical Pharmacology</u> Vol 15, (1956), 645-655	

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)	<i>Complete if Known</i>	
	<b>Application Number</b>	10/597,803
	<b>Filing Date</b>	April 13, 2007
	<b>First Named Inventor</b>	Robert Tridgett
	<b>Group Art Unit</b>	1614
	<b>Examiner Name</b>	Craig Ricci
Sheet 5 of 5	Attorney Docket No: 3063.002US1	

<b>OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS</b>		
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	USKOKOVIC, et al., "The Nuclear Magnetic Resonance Spectra of the Angular Proton in Benzo [a]-and Indolo[a]quinolizidines", <u>Journal of the American Chemical Society</u> 86 (16), (1964), 3364-67	
	ZUBIETA, et al., "High Vesicular Monoamine Transporter Binding in Asymptomatic Bipolar I Disorder: Sex Differences and Cognitive Correlates", <u>Am. J. Psychiatry</u> 157:10, (2000), 1619-1628	

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant is to place a check mark here if English language Translation is attached